Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by LARSEN, A.
Right arrow Articles by SVENSSON, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LARSEN, A.
Right arrow Articles by SVENSSON, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1989 British Society for Rheumatology

research-article

PODOPHYLLUM DERIVATIVES (CPH 82) COMPARED WITH PLACEBO IN THE TREATMENT OF RHEUMATOID ARTHRITIS

A. LARSEN1,*, I. PETERSSON{dagger} and B. SVENSSON{dagger}

*Department of Rheumatology, Västra sjukhuset Box 870, S-721 23 Västerá, Sweden
{dagger}Spenshult's Rheumatism Hospital S-313 00 Oskarström, Sweden

Correspondence to: 1Correspondence to Dr. Larsen.

The efficacy, tolerance, and safety of CPH 82 (semisynthetic lignan glycosides) (Conpharm AB) for patients with rheumatoid arthritis (RA) were assessed in a 12-week double-blind, placebo-controlled study. Thirteen patients out of 15 in the CPH 82 group and 10 out of 15 in the placebo group completed the study. No improvement was seen in placebo treated patients. Patients treated with CPH 82 showed a statistically significant improvement in most clinical and immunological variables. Some patients treated with CPH 82 reported gastrointestinal discomfort (diarrhoea and abdominal pain).

KEY WORDS: Disease modifying drugs, Second-line drugs


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
K. L. Soeken, S. A. Miller, and E. Ernst
Herbal medicines for the treatment of rheumatoid arthritis: a systematic review
Rheumatology, May 1, 2003; 42(5): 652 - 659.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. I. Catrina, J. Lampa, S. Ernestam, E. af Klint, J. Bratt, L. Klareskog, and A.-K. Ulfgren
Anti-tumour necrosis factor (TNF)-{alpha} therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis
Rheumatology, May 1, 2002; 41(5): 484 - 489.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
T. Lerndal and B. Svensson
A clinical study of CPH 82 vs methotrexate in early rheumatoid arthritis
Rheumatology, March 1, 2000; 39(3): 316 - 320.
[Abstract] [Full Text] [PDF]

Home page
 Hum Exp ToxicolHome page
W.-F. Kao, D.-Z. Hung, W.-J. Tsai, K.-P. Lin, and J.-F. Deng
Podophyllotoxin Intoxication: Toxic Effect of Bajiaolian in Herbal Therapeutics
Human and Experimental Toxicology, January 1, 1992; 11(6): 480 - 487.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.